Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis

Conclusion: FGL and NTZ were both well tolerated, but FGL less so than NTZ, especially in patients switching to FGL from NTZ. Group differences were not explained by differences in recorded baseline characteristics.

http://msj.sagepub.com/cgi/content/abstract/22/1/85?rss=1

Source: Multiple Sclerosis - December 18, 2015 Category: Neurology Authors: Frisell, T., Forsberg, L., Nordin, N., Kiesel, C., Alfredsson, L., Askling, J., Hillert, J., Olsson, T., Piehl, F. Tags: Original Research Papers Source Type: research